Aclaris Therapeutics Inc Cash Flow Conversion Efficiency
Aclaris Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has a cash flow conversion efficiency ratio of -0.091x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.93 Million) by net assets ($120.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aclaris Therapeutics Inc (2013–2024)
Cash flow conversion efficiency of Aclaris Therapeutics Inc from 2013 to 2024. This chart illustrates how Aclaris Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aclaris Therapeutics Inc stock quote for real-time trading data and today's change.
Aclaris Therapeutics Inc Cash Flow Conversion Ratio Explained
Aclaris Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aclaris Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aclaris Therapeutics Inc ranked by their cash flow conversion efficiency. Also see ACRS stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fine Semitech Corp
KQ:036810
|
-0.021x |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
0.119x |
|
Nanyang Senba Optical and Electronic Co Ltd
SHE:300701
|
0.034x |
|
Acco Brands Corporation
NYSE:ACCO
|
0.005x |
|
Ferm. Casino Mun. Canne
PA:FCMC
|
0.020x |
|
Beijing AriTime Intelligent Control Co Ltd
SHG:600560
|
-0.046x |
|
TARC Limited
NSE:TARC
|
0.245x |
|
FinVolution Group
F:PP3
|
0.028x |
Annual Cash Flow Conversion Efficiency for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Aclaris Therapeutics Inc from 2013 to 2024. Review Aclaris Therapeutics Inc (ACRS) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $155.55 Million | $-20.07 Million | -0.129x | +74.10% |
| 2023-12-31 | $157.18 Million | $-78.33 Million | -0.498x | -45.75% |
| 2022-12-31 | $197.62 Million | $-67.57 Million | -0.342x | -29.42% |
| 2021-12-31 | $197.34 Million | $-52.13 Million | -0.264x | +74.25% |
| 2020-12-31 | $37.65 Million | $-38.63 Million | -1.026x | +25.62% |
| 2019-12-31 | $69.91 Million | $-96.44 Million | -1.380x | -194.38% |
| 2018-12-31 | $215.12 Million | $-100.81 Million | -0.469x | -93.11% |
| 2017-12-31 | $225.26 Million | $-54.66 Million | -0.243x | -18.86% |
| 2016-12-31 | $169.49 Million | $-34.60 Million | -0.204x | +7.27% |
| 2015-12-31 | $92.52 Million | $-20.37 Million | -0.220x | -159.84% |
| 2014-12-31 | $-20.75 Million | $-7.64 Million | 0.368x | -31.48% |
| 2013-12-31 | $-9.16 Million | $-4.92 Million | 0.537x | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more